Reaction
Injection Site Atrophy reporting signals
As of the last recalculation, Injection Site Atrophy appears in 1,629 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is ASFOTASE ALFA (PRR 230.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Asfotase Alfa | 163 | 230.9 | 234.7 |
| Glatiramer Acetate | 323 | 85.9 | 86.4 |
| Triamcinolone Acetonide | 164 | 75.3 | 75.7 |
| Interferon Beta-1B | 66 | 45.8 | 46.0 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 36 | 20.1 | 20.1 |
| Interferon Beta-1A | 240 | 18.4 | 18.5 |
| Cabotegravir | 6 | 9.5 | 9.5 |
| Insulin Glulisine | 7 | 8.8 | 8.8 |
| Peginterferon Beta-1A | 9 | 8.8 | 8.8 |
| Medroxyprogesterone Acetate | 30 | 7.8 | 7.8 |
| Bupivacaine | 5 | 6.9 | 6.9 |
| Botulinum Toxin Type A | 6 | 6.2 | 6.2 |
| Dalfampridine | 19 | 3.4 | 3.4 |
| Somatropin | 18 | 3.2 | 3.2 |
| Onabotulinumtoxina | 17 | 2.8 | 2.8 |